93 Views | 60 Downloads
Conceived and designed the experiments: VdM YP MP. Performed the experiments: VdM HL JM AS. Analyzed the data: VdM YP MP. Wrote the paper: VdM MP.
The authors are grateful to graphic artist Kristin Johnson (Children's Hospital Boston, Boston, MA) for excellent assistance with photography.
Competing Interests: A patent has been issued to Dr. Puder and Children's Hospital Boston for the treatment of steatosis with the drug Marimastat. This manuscript shows the efficacy of this drug in a mouse model. The authors have no other proprietary information on the drug; therefore everything they know about it can be shared and is being shared with the reader of the manuscript. The drug is not owned by the authors or this institution. It was obtained from British Biotech (United Kingdom), and the drug and all rights were transferred to Vernalis (United Kingdom). Since Vernalis owns this drug, an interested party may contact the company and work out an agreement with them to obtain the drug. This agreement is the material transfer agreement. This is a common practice with proprietary drugs that are not on the market. Any and all information the authors have about the drug is open for disclosure from the authors but, as mentioned, is all in the manuscript.
VdM was recipient of fellowships from the foundations Stichting Profesor Michael-van Vloten Fonds (Venray, The Netherlands), VSBfonds (Utrecht, The Netherlands), Gerrit Jan Mulder Stichting (Rotterdam, The Netherlands), Prins Bernhard Cultuurfonds (Amsterdam, The Netherlands), and Dr Saal van Zwanenberg Stichting (Oss, The Netherlands). MP was supported by the Children's Hospital Boston Surgical Foundation and The Vascular Biology Program (Boston, Massachusetts), and the National Institutes of Health (grant DK069621). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
© 2011 de Meijer et al.